Reduction of plasma taurine level in children affected by Osteogenesis Imperfecta during bisphosphonate therapy

Biomedicine and Pharmacotherapy

Volumn 61, Issue 4, 2007, Pages 235-240

  D'Eufemia, Patrizia ^a   Finocchiaro, Roberto ^a   Zambrano, Anna ^a   Tetti, Martina ^a   Ferrucci, Valentina ^a   Celli, Mauro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Amino acids; Bisphosphonates; Children; Osteogenesis Imperfecta; Taurine

Indexed keywords

AMINO ACID DERIVATIVE; ARGININE; BISPHOSPHONIC ACID DERIVATIVE; HYDROXYPROLINE; LYSINE; NERIDRONIC ACID; TAURINE;

ABSENCE OF SIDE EFFECTS; AMINO ACID ANALYSIS; ARTICLE; BONE DENSITY; BONE METABOLISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; HUMAN; MALE; OSTEOGENESIS IMPERFECTA; PREPUBERTY; PRIORITY JOURNAL; URINARY EXCRETION;

AMINO ACIDS; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOGENESIS IMPERFECTA; TAURINE;

EID: 34247637939     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.11.005     Document Type: Article

References (25)

1. Sillence D. Osteogenesis Imperfecta. Bone 27 Suppl. 1 (2000) S4
2. Glorieux F., and Rauch F. Osteogenesis Imperfecta. Lancet 365 (2004) 1377-1385
3. Arikoski P., Silverwood B., Tillmann V., and Bishop N.J. Intravenous pamidronate treatment in children with moderate to severe Osteogenesis Imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first years of therapy. Bone 34 (2004) 539-546
4. DiMeglio L.A., Ford L., McClintock C., and Peacock M. Intravenous pamidronate treatment of children under 36 months of age with Osteogenesis Imperfecta. Bone 35 (2004) 1038-1045
5. Zeitlin L., Rauch F., Travers R., Munns C., and Glorieux F.H. The effect of cyclical intravenous pamidronate in children and adolescents with Osteogenesis Imperfecta type V. Bone 38 (2006) 13-20
6. Gatti D., Antoniazzi F., Prizzi A., Braga V., Rossini M., Tato' L., et al. Intravenous neridronate in children with Osteogenesis Imperfecta: a randomized controlled study. J Bone Miner Res 20 (2005) 758-763
7. Allgrove J. Use of bisphosphonates in children and adolescent. J Pediatr Endoscrinol Metab 15 (2002) 921-928
8. Van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264 (1999) 108-111
9. Toyras A., Ollikainen J., Taskinen M., and Monkkonen J. Inhibition of mevalonate pathway in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pham Sci 19 (2003) 223-230
10. Fleisch H. Bisphosphonates: mechanism of action. Endocrinol Rev 19 (2000) 80-100
11. Adami S., Bevilacqua M., Broggini M., Filipponi P., Ortolani S., Palummeri E., et al. Short-term intravenous therapy with neridronate in Paget's disease. Clin Exper Rheumatol 220 (2002) 55-58
12. Adami S., Gatti D., Colapietro F., Fracassi E., Braga V., Rossini M., et al. Intravenous neridronate in adults with Osteogenesis Imperfecta. J Bone Miner Res 18 (2003) 126-130
13. Torricelli P., Fini M., Giavaresi G., Giardino R., Gnudi S., Nicolini A., et al. l-Arginine and l-Lysine stimulation on cultured human osteoblast. Biomed Pharmacother 56 (2002) 492-497
14. Lubec B., Ya-hua Z., Pertti S., Pentti T., Kizmuller E., and Lubec G. Distribution and disappearance of the radiolabeled carbon derived from l-arginine and taurine in the mouse. Life Sci 60 (1997) 2373-2381
15. Terauchi A., Nakazaw A., Johkura K., Yan L., and Usuda N. Immunohistochemical localization of taurine in various tissue of the mouse. Amino Acid 15 (1998) 151-160
16. Koide M., Okahashi N., Tanaka R., Kazuno K., Shibasaki K., Yamazaki Y., et al. Inhibition of experimental bone resorption and osteoclast formation and survival by 2-aminoethanesulphonic acid. Arch Oral Biol 44 (1999) 711-719
17. Gupta R.C., Win T., and Bitter S. Taurine analogues; a new class of therapeutics: retrospect and prospect. Curr Med Chem 1247 (2005) 2021-2039
18. Kum K.Y., Park Y.H., Yoo Y.J., Choi B.K., Lee H.J., and Lee S.J. The inhibitory effect of alendronate and taurine on osteoclast differentiation mediated by porphyromonas gengivalis sonicates in vitro. J Endodon 29 (2003) 28-30
19. Sillence D.O., Seen A., and Danks D.M. Genetic heterogeneity in Osteogenesis Imperfecta. J Med Genet 16 (1979) 101-116
20. Cohen S.A., Bidlingmeyer B.A., and Tarvin T.L. PITC derivatives in amino acid analysis. Nature 320 (1986) 769-770
21. Sturman J.A., and Hayes K.C. The biology of taurine in nutrition and development. In: Draper H.H. (Ed). Advances in nutritional research (1980), Plenum Publishing Corp, New York 231-299
22. Huxtable R.J. Physiological action of taurine. Physiol Rev 72 (1992) 101-163
23. Park S., Kim H., and Kim S.J. Stimulation of ERK2 by taurine with enhanced alkaline phosphatase activity and collagen synthesis in osteoblast-like UMR-106 cells. Biochem Pharmac 62 (2001) 1107-1111
24. Fleish H. Bisphosphonates in osteoporosis. Eur Spine J 12 Suppl. 2 (2003) S142-S146
25. Shaw N.J., and Bishop N.J. Bisphosphonate treatment of bone disease. Arch Dis Child 90 (2005) 494-499